AIDS Funding Shifts to the Laboratory

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 4
Volume 4
Issue 4

WASHINGTON--William Paul, MD, director of the NIH Office of AIDS Research, has announced that AIDS funding will begin to shift away from clinical research toward investigator-initiated laboratory research. He said that continuation of past policies will result in only "slow, fitful progress."

WASHINGTON--William Paul, MD, director of the NIH Office of AIDSResearch, has announced that AIDS funding will begin to shiftaway from clinical research toward investigator-initiated laboratoryresearch. He said that continuation of past policies will resultin only "slow, fitful progress."

Dr. Paul appointed a new task force, chaired by Arnold Levine,a Princeton University molecular biologist, to determine researchpriorities.

Recent Videos
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.
Ronald Bleday, MD, credits a chronic pain clinic for consulting patients who may be at a greater risk for prolonged opioid use following surgery.
Related Content